Efficiency of New Dose Escalation Designs in Dose-Finding Phase I Trials of Molecularly Targeted Agents

Open Access

Peer-reviewed

Research Article

Christophe Le Tourneau ,

* E-mail: Christophe.LeTourneau@curie.net

Affiliations Department of Medical Oncology, Institut Curie, Paris, France, Institut Curie / INSERM U900, Paris, France
⨯
Hui K. Gan,

Affiliation Joint Austin-Ludwig Oncology Unit, Austin Hospital, Melbourne, Australia
⨯
Albiruni R. A. Razak,

Affiliation Department of Medical Oncology, Princess Margaret Hospital, Toronto, Canada
⨯
Xavier Paoletti

Affiliations Department of Biostatistics, Institut Curie, Paris, France, Institut Curie / INSERM U900, Paris, France
⨯

Reader Comments (0)

Phase I clinical investigation
Is the Subject Area "Phase I clinical investigation" applicable to this article?

Thanks for your feedback.
Toxicity
Is the Subject Area "Toxicity" applicable to this article?

Thanks for your feedback.
Cancers and neoplasms
Is the Subject Area "Cancers and neoplasms" applicable to this article?

Thanks for your feedback.
Clinical trials (cancer treatment)
Is the Subject Area "Clinical trials (cancer treatment)" applicable to this article?

Thanks for your feedback.
Toxic agents
Is the Subject Area "Toxic agents" applicable to this article?

Thanks for your feedback.
Algorithms
Is the Subject Area "Algorithms" applicable to this article?

Thanks for your feedback.
Phase II clinical investigation
Is the Subject Area "Phase II clinical investigation" applicable to this article?

Thanks for your feedback.
Clinical trials
Is the Subject Area "Clinical trials" applicable to this article?

Thanks for your feedback.